Acute Myeloid Leukemia Flt3 Tyrosine Kinase Domain Point Mutation Cn305573
A mutation in the FLT3 gene that promotes abnormal blood cell production. It occurs in AML patients and affects prognosis. Treated with targeted inhibitors and chemotherapy.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Fever
Bleeding or bruising
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Fatigue
(general)Bone pain
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
FLT3 TKI Monotherapy or Combination
Second-generation FLT3 inhibitors like gilteritinib may offer improved targeting of TKD mutations compared to earlier agents. Treatment can be given alone or combined with other agents depending on disease status and treatment phase.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Stem Cell Transplant Consultation
Referral for transplant evaluation to assess candidacy for allogeneic transplantation. TKD mutations may have different prognostic implications than ITD, affecting transplant decision-making.
Additional treatment options
Molecular Response Assessment
Quantitative PCR or NGS-based monitoring of FLT3 TKD mutations throughout treatment. Deep molecular response correlates with improved progression-free survival.
monitoringSupportive Care and Infection Prophylaxis
Comprehensive supportive care including antimicrobial prophylaxis, growth factor support, and transfusion support. Addresses complications from both disease and targeted therapy.
medicationSpecialized Enteral or Parenteral Nutrition
Nutritional intervention when oral intake is inadequate, including tube feeding or intravenous nutrition support. Maintains protein-energy status and micronutrient levels during intensive treatment phases.
dietaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia Flt3 Tyrosine Kinase Domain Point Mutation Cn305573?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of AML in adults: recommendations from an international expert panel. Blood. 2017.
Kiyoi H, Kawashima M, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: biological characteristics and therapeutic implications. Leuk Lymphoma. 2020.
Levis MJ, Perl AE, Altman JK, et al. A phase 1 trial of gilteritinib in combination with azacitidine in FLT3-mutated acute myeloid leukemia. Blood Adv. 2021.
Wang ES, Ritchie DS, Smith CC. FLT3 inhibitors for the treatment of acute myeloid leukemia: a systematic review of clinical trials. J Clin Oncol. 2022.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia Flt3 Tyrosine Kinase Domain Point Mutation Cn305573. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy